For the first time, OncoDxRx has presented its most advanced minimal residual disease (MRD) technology, the OncoMRD BREAST test, in the prestigious journal Onco (https://www.mdpi.com/2673-7523/5/3/35) published by MDPI.
The precision functional genomics company OncoDxRx unveiled its proprietary OncoMRD assay for monitoring residual disease, an advanced "personalized gene signature” designed for high-precision, simultaneous detection of critical tumor and non-tumor biomarkers.
Some patients who receive targeted drugs or immunotherapy experience significant benefit in terms of tumor shrinkage and longer survival as responders — but many do not (i.e., non-responders). A new study suggests that measuring overactive genes in the blood could help doctors determine which drugs are most likely to benefit individual non-responders.
OncoDxRx, a California-based liquid biopsy startup, builds gene expression-powered treatment selection technology that helps clinicians identify the most suitable drugs for individual patients who are not responding to current therapies.
OncoDxRx announced a new cfmRNA-based MRD assay creatively named OncoMRD (OncoDxRx’s monitoring residual disease), which the company said is based on its in-service patient-derived gene expression signature.
Minimal residual disease (MRD) testing, like OncoDxRx's OncoMRD, appears to be a valuable tool for predicting outcomes and potential relapse in patients with cancer.
OncoDxRx’s PGA test provides access – the ability to find a way around. The one-of-a-kind technology can “re-measure the geometry of the tumor with regard to access to more therapeutic options”.
A new "build-for-purpose” test was unveiled by OncoDxRx. The proprietary technology aims at broadening the coverage of tailored personalized diagnostics and therapeutics to those cancer patients currently excluded from precision medicine.
Satisfied Users & 
Approved Press Releases
